NASDAQ Gainers: Ariad Pharmaceuticals (NASDAQ:ARIA), Yandex NV (NASDAQ:YNDX), GT Advanced Technologies (NASDAQ:GTAT), Oculus Innovative Sciences (NASDAQ:OCLS)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Net loss for the fourth quarter ended December 31, 2013 was $74.2 million, or $0.40 per share, compared to a net loss of $60.5 million, or $0.36 per share, for the same period in 2012. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock … Continue reading NASDAQ Gainers: Ariad Pharmaceuticals (NASDAQ:ARIA), Yandex NV (NASDAQ:YNDX), GT Advanced Technologies (NASDAQ:GTAT), Oculus Innovative Sciences (NASDAQ:OCLS)

Biotech Gainers: Geron Corporation (NASDAQ:GERN), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Opexa Therapeutics Inc. (NASDAQ:OPXA)

Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Geron Corporation (NASDAQ:GERN) securities during the period between June 16, 2013 and March 11, 2014, inclusive (the “Class Period”). Geron Corporation (NASDAQ:GERN) stock performance was 39.33% in last session and finished the day at … Continue reading Biotech Gainers: Geron Corporation (NASDAQ:GERN), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Opexa Therapeutics Inc. (NASDAQ:OPXA)

The iShares Biotechnology Indexhas fallen 2.46% in the last month of trading, and biotech stalwarts Celgene (NASDAQ:CELG) and Gilead Sciences (NASDAQ:GILD ) are both down over 8%. What’s most surprising is that Celgene and Gilead are expected to have strong years in terms of earnings and the development of their respective clinical pipelines. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 0.53% in last session and … Continue reading Biotech Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Inovio Pharmaceuticals Inc (NYSEMKT:INO), Geron Corporation (NASDAQ:GERN)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Feb. 25 reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was 8.79% in last session and finished the day at $8.17. Traded volume was 18.32 million shares in the last session and the average volume of the stock remained 16.55 million … Continue reading Biotech Top Gainer: Ariad Pharmaceuticals (NASDAQ:ARIA), CEL-SCI Corporation (NYSEMKT:CVM), Synthetic Biologics (NYSEMKT:SYN), Agenus Inc. (NASDAQ:AGEN)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Net loss for the fourth quarter ended December 31, 2013 was $74.2 million, or $0.40 per share, compared to a net loss of $60.5 million, or $0.36 per share, for the same period in 2012. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock … Continue reading Biotech Active Runners: Ariad Pharmaceuticals (NASDAQ:ARIA), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX), announced on Thursday that the Biomedical Advanced Research and Development authority extended the base period of performance of a contract with the pharmaceutical company for its recombinant seasonal and pandemic influenza vaccines. Novavax, Inc. (NASDAQ:NVAX) stock performance was 1.27% in last session and finished the day at $6.38. Traded volume was 13,436,282 million shares in the last session and the average volume … Continue reading Biotech Active Runners: Novavax (NASDAQ:NVAX), VIVUS (NASDAQ:VVUS), Rexahn Pharmaceuticals (NYSEMKT:RNN), Ariad Pharmaceuticals (NASDAQ:ARIA)